$8 Billion Opportunity: Inhibrx’s Experimental Cancer Drug Draws Major Interest
Inhibrx is drawing strong interest from Merck and other big pharma for its experimental cancer drug INBRX-106 that could boost Keytruda. Potential $9B spin-off value.
/ 24 items
#MRK↓
Merck and Eisai Phase 3 Miss Shakes Up Kidney Cancer Race – Analysts Split on Arcus
Merck’s new kidney cancer combos failed in Phase 3, missing key goals; analysts see mixed impact for Arcus and its drug.
Stifel Sees 134% Upside in Summit Therapeutics as Ivonescimab Eyes $200B Market
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
Why Merck’s Big CML Bet Makes Enliven’s ELVN-001 a Takeover Star
Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
Merck Buys Terns Pharmaceuticals for $6.7 Billion to Boost Blood Cancer Pipeline with Promising CML Drug
Merck is buying Terns Pharmaceuticals for $6.7 billion to add TERN-701, a promising new oral drug for chronic myeloid leukemia (CML). The move strengthens its cancer pipeline as Keytruda patent expiry nears in 2028.
Merck Ends Talks to Buy Cancer Biotech Revolution Medicines in $30B Deal
Merck has walked away from negotiations to acquire Revolution Medicines after failing to agree on price for the promising cancer drug developer valued around $30 billion.